Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move (CSE: $DOSE.C) (TSXV: $RIV.V) (CSE: $FONE.C) (CSE: $ROMJ.C)
Delta, Kelowna, BC –July 16, 2019 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s edition of Investorideas.com potcastsCM - cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com “potcasts”, looking at cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we look at a few early announcements.
But first, CannabCo Pharmaceutical Corp. Colombia S.A.S., a Colombia based cannabis cultivator and manufacturer of medical cannabis products, announced that it has completed a definitive agreement with Invest In Orinoquia for the development of thousands of hectares of Cannabis and hemp production in the Los Llanos region of Colombia. The joint venture will proceed with the deployment of "purpose-built" cannabis greenhouses for the cultivation of cannabis under the medical production laws of Colombia in the Los Llanos region of the country near Villavicencio. The project has been funded for an initial 5 hectare (538,000 sq/ft) build-out with potential expansion to 240 Hectares of Cannabis cultivation over the next 5 years.
“We are thrilled to be working with CannabCo on a project of this magnitude." said Didier Valek, the Executive Director of Invest in Orinoquia. "It was important for us to find the right company for the development of cannabis within the region and we were impressed with CannabCo's vast knowledge base, professionalism, and existing footprint in Colombia, making them the perfect choice for a project of this size."
After the initial build-out, CannabCo is looking to expand rapidly on the footprint with a virtually unlimited amount of land available to the company and the project. The Los Llanos region features the perfect environment for growing Cannabis, with an ample amount of sunlight, water availability, and a stable annual temperature perfect for cultivation. CannabCo estimates at least 4 crop rotations per annum yielding an abundance of high quality product slated for extraction to Cannabis oil. The project will be ICA certified (Colombia's "Agriculture Institute") and follows GACP and GPP practices for the cultivation of a food-grade / medical crop.
Already projected to be one of the largest cannabis producers globally, this latest initiative secures CannabCo as a primary source for medical Cannabis extracts and products for both domestic supply and export markets. In addition to the Los Llanos project, the company recently completed an agreement for the conversion of approximately 1 Million Sq/ft of greenhouse production in the Cundinamarca region for cannabis cultivation.
"As an addition to our current operations, this latest agreement fits perfectly with the company's goals to be the world leader in cannabis production. We have established the perfect relationship with Invest in Orinoquia to assist Colombia in becoming the primary source for medical cannabis globally," said Joseph Palumbo, CannabCo's General Manager for Colombia, "Our goal is to increase our cultivation footprint, product manufacturing, and supply infrastructure to become the largest quality supplier of medical cannabis in the world," said Joseph.
Cannabco will be providing genetics for cultivation specific to the Los Llanos region to maximize productivity, yields, and resistance to local pathogens. Through the use of targeted genetics, and purpose-built cannabis greenhouses, management intends for Cannabco's operations to be the most advanced and productive cultivation operation in South America.
The project is fully funded and is slated to begin in 2019. Once completed, the project will begin grow operations and aggressive expansion efforts with the construction of additional purpose built greenhouses under the CannabCo License.
"While our primary focus is on medical Cannabis, we will be pursuing parallel initiatives such as hemp production and hemp derived CBD to meet market demand and requests for product from our supply channel." said Joseph.
Rapid Dose Therapeutics Corp. (CSE: DOSE) and Ukraine Pharma announced today that they have signed a twelve month distribution agreement to export QuickStrip™ nutraceutical products to Ukraine and a number of other Eastern European countries, giving the Company rights to market the Energy, B12, and Sleep QuickStrip™ nutraceutical products to a consumer base of over 200 million people with tremendous buying power.
The Agreement requires a minimum quarterly order of one million of each of RDT's Energy, B12, and Sleep QuickStrips™ and the Company has provided RDT with a signed purchase order for US$2.1 million.
RDT's proprietary QuickStrip™ technology is a Quick, Convenient, Precise, Discreet™ oral fast-dissolving drug delivery system that offers an Anytime, Anywhere™ product to consumers. Ukraine Pharma expects to distribute QuickStrip™ by the third calendar quarter of 2019.
"This represents the beginning of a growing opportunity for RDT to provide its QuickStrip™ products to people wanting an effective and innovative means of delivering nutraceuticals," said Mark Upsdell, CEO of RDT. "The Agreement with Ukraine Pharma elevates QuickStrip™ as a growing international brand and delivery device to major market consumers, while simultaneously offering health benefits and improving patient outcomes."
"When we were introduced to the QuickStrip™ technology and nutraceutical product line, we knew this will significantly change the way drugs are delivered," said Veronica Burke, CEO of Ukraine Pharma. "The high quality product combined with the innovative delivery system is something we consider is much needed in the numerous Eastern European countries in which we have established relationships. We will begin distribution in Ukraine and expand from there."
Canopy Rivers Inc. (TSXV: RIV) (OTC: CNPOF) today released its financial results for the three and twelve months ended March 31, 2019. The Company's audited consolidated financial statements for the twelve months ended March 31, 2019, and its full Management's Discussion and Analysis for the three and twelve months ended March 31, 2019, are available under the Company's profile on the System for Electronic Document Analysis and Retrieval at www.sedar.com and on the Company's website at www.canopyrivers.com/financials.
"It was a year full of milestones and significant achievements for Canopy Rivers," said Narbe Alexandrian, President and Chief Executive Officer of Canopy Rivers. "Anchored by our go public transaction and listing on the TSX Venture Exchange, eight new investments, and landmark transactions for certain portfolio companies, we have strategically positioned ourselves as an accelerator of growth for companies that we believe are situated to be leaders in the cannabis industry. We are excited for the future as we continue to discover, evaluate, and invest in ways that expand our footprint into new channels and markets globally, ultimately creating value for our shareholders," continued Alexandrian. "With positive global sentiment towards cannabis on the rise, and Canada's legalization of edibles, extracts, and topicals coming into force in the fall, we are optimistic about the growth potential of the cannabis industry in the coming years."
"With more than $195 million in gross proceeds raised from equity financings and more than $115 million of capital deployed into new and existing investments over fiscal 2019, we continue to position ourselves as leading allocators of capital in this new and emerging global industry," said Eddie Lucarelli, Chief Financial Officer of Canopy Rivers. "This past fiscal year represented a period of significant capacity build-out and operational investment at our portfolio companies. We are excited to see our partners complete their build-out activities over the next few quarters, allowing their underlying businesses to scale and accelerate their individual paths towards the generation of meaningful EBITDA across the Company's ecosystem."
Flower One Holdings Inc. (CSE: FONE) (OTCQB: FLOOF) today announced a long-term licensing agreement with Denver-based Clear Cannabis, Inc. – who licenses The Clear™, one of eight marquee brands licensed under its parent company. The Clear product suite was founded by scientists and engineers with substantial expertise in chemistry, biology, and engineering, and the vision of carving out a unique space within the cannabis industry. The Clear is the first manufacturer to bring pure, refined cannabis oil to market globally. Flower One is now licensed to produce, manufacture, and distribute The Clear's product to Nevada's cannabis retailers, providing the state's consumers with a consistent supply of The Clear's popular line of flavorful cannabis oils.
"We are excited to welcome The Clear to Flower One's growing portfolio of Brand Partners," said Ken Villazor, President and CEO of Flower One. "This is our tenth brand partnership to date, aligning with our commitment to expand the range of cannabis products available to cannabis retailers and consumers in Nevada, and to contribute to the growing product diversity of the State's retail market."
Founded in 2013, The Clear has established itself as the first and original cannabis distillation company. Featuring a robust menu of 17 flavorful vape cartridges, among other high-quality products, The Clear utilizes steam-distilled plant extracts and unmatched state-of-the-art technology to provide consumers with a reliable, clean, and consistent cannabis experience. Soon The Clear's C-Cell cartridges and top pull batteries will be available in Nevada, providing cannabis consumers with a consistent dosing experience. Additional vape cartridges will follow later this year.
Rubicon Organics Inc. (CSE:ROMJ) (OTCQX:ROMJF) announced that it has received organic certification from the Fraser Valley Organics Producers Association at its flagship 125,000-square-foot hybrid greenhouse facility in Delta, BC. As a result, the Company is now positioned to supply certified organic, super-premium cannabis grown at scale to a market where organic products are in high demand, short supply and priced at significant premiums.
"Organic cannabis is highly coveted in the medical and over-the-counter markets in North America and Europe," said Jesse McConnell, Chief Executive Officer and Co-Founder of Rubicon Organics. "Due to a substantial lack of supply of high-quality cannabis in the marketplace, there is currently a 40% to 50% price premium for super-premium cannabis products and an additional 25% to 50% price premium for organic products in Canada. This is the market that Rubicon Organics is now well-positioned to serve."
"Having organic certification from FVOPA is unequivocal validation of our proven, proprietary organic cultivation methodology which we expect will produce super-premium, certified organic cannabis at scale and at a competitive cost. For investors, this means the company expects to achieve industry-leading gross margins and profitability. For the consumer, Rubicon Organics will deliver a connoisseur-level experience with the cleanest and most terpene-rich products on the market."
Rubicon Organics is currently one of just two cannabis companies in Canada to be certified by FVOPA, Canada's preeminent certification body for organic operators. FVOPA's rigorous certification program is compliant with International Organization for Standardization (ISO) 17065, Canadian Organic Standards and BC Certified Organic programs.
Rubicon Organics' cannabis is grown in a proprietary 100% organic soil and fertilizer mix made in-house and developed over years of organic cannabis cultivation, research and development by the Company's CSO, who also wrote the Certified Organic Cannabis Standard in Canada for FVOPA. Rare and semi-rare cannabis strains are grown without herbicides or pesticides in a sophisticated hybrid greenhouse environment with exposure to natural sunlight and a fully automated climate control system ensuring optimal growing conditions year-round.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and the AI Eye Podcast and column covering developments in AI.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
